Pathstone Family Office’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $12.3M | Buy |
24,349
+12,416
| +104% | +$6.62M | 0.09% | 145 |
|
|
2023
Q2 | $6.08M | Buy |
11,933
+378
| +3% | +$204K | 0.09% | 146 |
|
|
2023
Q1 | $6.84M | Sell |
11,555
-23,035
| -67% | -$13M | 0.11% | 129 |
|
|
2022
Q4 | $13.2M | Buy |
34,590
+6,386
| +23% | +$3.38M | 0.11% | 142 |
|
|
2022
Q3 | $14.3M | Buy |
28,204
+23,837
| +546% | +$13.3M | 0.13% | 108 |
|
|
2022
Q2 | $2.37M | Buy |
4,367
+1,851
| +74% | +$1.02M | 0.05% | 187 |
|
|
2022
Q1 | $1.5M | Sell |
2,516
-107
| -4% | -$61.5K | 0.03% | 229 |
|
|
2021
Q4 | $1.75M | Buy |
2,623
+135
| +5% | +$84.3K | 0.04% | 214 |
|
|
2021
Q3 | $1.42M | Buy |
2,488
+482
| +24% | +$265K | 0.04% | 217 |
|
|
2021
Q2 | $1.01M | Buy |
2,006
+628
| +46% | +$296K | 0.03% | 269 |
|
|
2021
Q1 | $629K | Buy |
1,378
+1,128
| +451% | +$538K | 0.02% | 299 |
|
|
2020
Q4 | $117K | Buy |
250
+136
| +119% | +$63.8K | ﹤0.01% | 354 |
|
|
2020
Q3 | $50K | Hold |
114
| – | – | 0.01% | 372 |
|
|
2020
Q2 | $42K | Hold |
114
| – | – | 0.01% | 338 |
|
|
2020
Q1 | $32K | Buy |
114
+1
| +0.9% | +$315 | ﹤0.01% | 363 |
|
|
2019
Q4 | $367K | Sell |
113
-23
| -17% | -$6.97K | ﹤0.01% | 334 |
|
|
2019
Q3 | $40K | Hold |
136
| – | – | 0.01% | 303 |
|
|
2019
Q2 | $40K | Buy |
136
+25
| +23% | +$6.89K | ﹤0.01% | 358 |
|
|
2019
Q1 | $30K | Sell |
111
-482
| -81% | -$120K | ﹤0.01% | 379 |
|
|
2018
Q4 | $133K | Buy |
593
+541
| +1,040% | +$127K | 0.04% | 111 |
|
|
2018
Q3 | $13K | Sell |
52
-45
| -46% | -$10.4K | ﹤0.01% | 155 |
|
|
2018
Q2 | $20K | Sell |
97
-7
| -7% | -$1.49K | 0.01% | 105 |
|
|
2018
Q1 | $21K | Buy |
104
+45
| +76% | +$9.45K | 0.01% | 157 |
|
|
2017
Q4 | $11K | Sell |
59
-203
| -77% | -$38.9K | 0.01% | 105 |
|
|
2017
Q3 | $50K | Sell |
262
-7
| -3% | -$1.27K | 0.05% | 73 |
|
|
2017
Q2 | $47K | Sell |
269
-28
| -9% | -$4.7K | 0.02% | 201 |
|
|
2017
Q1 | $45K | Buy |
+297
| New | +$45.4K | 0.02% | 188 |
|
|
2016
Q4 | – | Sell |
-283
| Closed | -$45K | – | 195 |
|
|
2016
Q3 | $45K | Sell |
283
-18
| -6% | -$2.77K | 0.05% | 67 |
|
|
2016
Q2 | $45K | Sell |
301
-75
| -20% | -$11.1K | 0.04% | 60 |
|
|
2016
Q1 | $54K | Buy |
376
+301
| +401% | +$40.3K | 0.11% | 51 |
|
|
2015
Q4 | $11K | Sell |
75
-30
| -29% | -$4K | 0.05% | 51 |
|
|
2015
Q3 | $13K | Buy |
+105
| New | +$13.7K | 0.04% | 71 |
|
|
2014
Q4 | – | Sell |
-410
| Closed | -$50K | – | 249 |
|
|
2014
Q3 | $50K | Buy |
+410
| New | +$49.9K | 0.16% | 50 |
|
Other funds holding TMO
Pathstone Family Office's TMO Position: Q3 2023 in Review
Pathstone Family Office increased its Thermo Fisher Scientific (TMO) stake by 104% in Q3 2023, buying an estimated $6.62M and bringing the position to 24,349 shares worth $12.3M. The position accounts for 0.09% of the portfolio, ranked #145.
Pathstone Family Office first reported a position in TMO in Q3 2014 and has held it in 33 quarters since. The position peaked at $14.3M in Q3 2022. 2,364 funds tracked by Wall St. Rank hold TMO as of Q3 2023.
- Pathstone Family Office held 24,349 shares of Thermo Fisher Scientific worth $12.3M as of Q3 2023.
- Pathstone Family Office bought 12,416 Thermo Fisher Scientific shares in Q3 2023, an estimated $6.62M.
- Thermo Fisher Scientific made up 0.09% of Pathstone Family Office's portfolio in Q3 2023, its #145 holding.
- Pathstone Family Office first reported a position in Thermo Fisher Scientific in Q3 2014 and has held it in 33 quarters since.
- Pathstone Family Office's Thermo Fisher Scientific position peaked at $14.3M in Q3 2022.
- 2,364 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.